Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048006 | 0.86 | TP53 (0.49) | HSD17B10LMNATARBP2POLBTP53 | |
| SCHEMBL13179907 | 0.85 | HSD17B10 (0.58) | HSD17B10LMNATARBP2THRBPOLB | |
| SCHEMBL924162 | 0.85 | HSD17B10 (0.54) | HSD17B10LMNATARBP2THRBPOLB | |
| SCHEMBL1051790 | 0.84 | NOTUM (0.45) | HSD17B10POLBTP53MAPTPPARA | |
| SCHEMBL203871 | 0.83 | HSD17B10 (0.53) | HSD17B10LMNATARBP2THRBPOLB | |
| SCHEMBL5762006 | 0.83 | HSD17B10 (0.56) | HSD17B10LMNATARBP2THRBPOLB | |
| SCHEMBL5540713 | 0.83 | HSD17B10 (0.53) | HSD17B10LMNATARBP2THRBPOLB | |
| SCHEMBL4830096 | 0.83 | TARBP2 (0.50) | HSD17B10LMNATARBP2TP53MAPT | |
| SCHEMBL1051419 | 0.83 | KDM4E (0.60) | LMNATARBP2TP53MAPTPPARA | |
| SCHEMBL1049626 | 0.83 | ALDH1A1 (0.51) | POLBTP53MAPTPPARATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| EP-1425014-B1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6884812-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | HSD17B10 325/4885LMNA 1312/4885TARBP2 3329/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | HSD17B10 245/4885LMNA 1215/4885TARBP2 3210/4885 |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, LIPA | HSD17B10 254/4885LMNA 1198/4885TARBP2 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.